CO.DON AG: EU-approved medicinal product receives vote for indication extension for use in adolescents

Teltow (pta001/22.05.2021/00:01 UTC+2) Teltow / Leipzig, 21 May 2021 - CO.DON AG (ISIN: DE000A1K0227) received today the positive vote of the CHMP (Committee for Medicinal Products for Human Use) of the EMA (European Medicines Agency) on the approval of the application for the indication extension of the EU-wide approved medicinal product for human use "Spherox - Spheroids from human autologous matrix-associated chondrocytes" for the use in adolescents.

The CHMP's assessment is the basis for the European Commission's decision on the EU-wide authorisation of the indication extension. In the past, the European Commission followed the recommendations of the CHMP in the vast majority of applications.

With the expanded indication for the EU, the treatment of symptomatic articular cartilage defects of ICRS Grade III or IV of the femoral condyle and the patella of the knee with defect sizes of up to 10 cm^2 is now also possible in adolescents with closed growth plates in addition to adult patients.

Notifying person: Tilman Bur, Management Board

Contact
Matthias Meißner
Director Corporate Communications
Investor Relations / Public Relations
T: +49 (0)341 99190 330
F: +49 (0)341 99190 309
E: ir@codon.de

(end)

Emitter:	CO.DON AG Warthestraße 21 14513 Teltow Germany
Contact Person:	Matthias Meißner
Phone:	+49 341 99190330
E-Mail:	ir@codon.de
Website:	www.codon.de
ISIN(s):	DE000A1K0227 (Share)
Stock Exchange(s):	Regulated Market in Frankfurt; Free Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate